NCT01684098View on ClinicalTrials.gov

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

August 31, 2005

Conditions
Recurrent or Metastatic CancerHead and Neck CancerPancreas CancerBladder CancerTesticular Cancer
Interventions
DRUG

Tc 99m EC20

Sponsors

Lead Sponsor

Endocyte
All Listed Sponsors
lead

Endocyte

INDUSTRY

NCT01684098 - Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | Biotech Hunter | Biotech Hunter